Panel says NSAID labels should not change

Share this article:

An FDA advisory panel said naproxen should not get a heart-friendly label that would indicate it may have a cardiovascular edge over other drugs in its drug class. Medpage Today reports the advisory panel voted 16-9 against a new label, saying there was insufficient evidence to support a change.

The "no" vote does not mean panelists do not think drugs like Aleve may have an edge over other medications. “If I were forced to bet on what the truth is, my bet would be that naproxen is safer,” Susan Ellenberg told the Associated Press.

The panel's decision followed two days of discussions which were prompted by more than 700 studies finding fewer heart problems with OTC and prescribed naproxen compared to other NSAIDs.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.